Photodynamic diagnosis of gastric cancer and esophageal cancer using fluorescence diagnosis with 5-aminolevulinic acid (5-ALA)

Photodynamic diagnosis of gastric cancer and esophageal cancer using fluorescence diagnosis with 5-aminolevulinic acid (5-ALA) - Photodynamic diagnosis of gastric cancer and esophageal cancer using fluorescence diagnosis with 5-aminolevulinic acid (5-ALA)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021288

Enrollment

100

Registered

2016-04-01

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer, esophageal cancer

Interventions

5-aminolevulinic acid (5-ALA) (unapproved drug by Japanese pharmaceutical affairs law) dissolved in 50mL of 5% glucose solution. 5-ALA solution was administered either way of following: Orally(1.0

180-240minutes before operation Instilled intravesically(1.5g/50mL)

90-120 minutes before operation. For fluorescence excitation a blue light source was used. Under white and fluorescence light guidance outputted by light source apparatus (D-Light AF System) and v

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient who was diagnosed as gastric cancer or esophageal cancer.

Exclusion criteria

Exclusion criteria: patient who has potential complication of local disorder and systematic absorption of 5-ALA such as solar photosensitivity and liver dysfunction

Design outcomes

Primary

Measure	Time frame
efficacy	—

Countries

Japan

Contacts

Public ContactTakahashi Tsuyoshi

Osaka University Graduate School of Medicine Department of Gastroenterological Surgery

ttakahashi2@gesurg.med.osaka-u.ac.jp+81-6-6879-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026